10. REFERENCES
1.Albers, P., et al. Guidelines on Testicular Cancer: 2015 Update. Eur Urol, 2015. 68: 1054.
https://pubmed.ncbi.nlm.nih.gov/26297604/
2.Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008. 336: 995.
https://pubmed.ncbi.nlm.nih.gov/18456631/
3.Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008. 336: 924.
https://pubmed.ncbi.nlm.nih.gov/18436948/
4.Phillips, B., et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.
https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
5.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://pubmed.ncbi.nlm.nih.gov/18467413/
6.Park, J.S., et al. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore), 2018. 97: e12390.
https://pubmed.ncbi.nlm.nih.gov/30213007/
7.Nigam, M., et al. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol, 2014.
https://pubmed.ncbi.nlm.nih.gov/25030752/
8.Gurney, J.K., et al. International Trends in the Incidence of Testicular Cancer: Lessons from 35 Years and 41 Countries. Eur Urol, 2019. 76: 615.
https://pubmed.ncbi.nlm.nih.gov/31324498/
9.Oosterhuis, J.W., et al. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer, 2005. 5: 210.
https://pubmed.ncbi.nlm.nih.gov/15738984/
10.Looijenga, L.H.J., et al. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors. Am J Surg Pathol, 2020. 44: e66.
https://pubmed.ncbi.nlm.nih.gov/32205480/
11.Jorgensen, N., et al. Testicular dysgenesis syndrome comprises some but not all cases of hypospadias and impaired spermatogenesis. Int J Androl, 2010. 33: 298.
https://pubmed.ncbi.nlm.nih.gov/20132348/
12.Lip, S.Z., et al. A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Arch Dis Child, 2013. 98: 20.
https://pubmed.ncbi.nlm.nih.gov/23193201/
13.Del Giudice, F., et al. Association between male infertility and male-specific malignancies: systematic review and meta-analysis of population-based retrospective cohort studies. Fertil Steril, 2020. 114: 984.
https://pubmed.ncbi.nlm.nih.gov/32709378/
14.Slowikowska-Hilczer, J., et al. Risk of gonadal neoplasia in patients with disorders/differences of sex development. Cancer Epidemiol, 2020. 69: 101800.
https://pubmed.ncbi.nlm.nih.gov/32905884/
15.Mostert, M.M., et al. Comparative genomic hybridization of germ cell tumors of the adult testis: confirmation of karyotypic findings and identification of a 12p-amplicon. Cancer Genet Cytogenet, 1996. 89: 146.
https://pubmed.ncbi.nlm.nih.gov/8697422/
16.Bosl, G.J., et al. Testicular germ-cell cancer. N Engl J Med, 1997. 337: 242.
https://pubmed.ncbi.nlm.nih.gov/9227931/
17.Greene, M.H., et al. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer, 2010. 17: R109.
https://pubmed.ncbi.nlm.nih.gov/20228134/
18.Lutke Holzik, M.F., et al. Genetic predisposition to testicular germ-cell tumours. Lancet Oncol, 2004. 5: 363.
https://pubmed.ncbi.nlm.nih.gov/15172357/
19.Kharazmi, E., et al. Cancer Risk in Relatives of Testicular Cancer Patients by Histology Type and Age at Diagnosis: A Joint Study from Five Nordic Countries. Eur Urol, 2015. 68: 283.
https://pubmed.ncbi.nlm.nih.gov/25913387/
20.Schaapveld, M., et al. Risk and prognostic significance of metachronous contralateral testicular germ cell tumours. Br J Cancer, 2012. 107: 1637.
https://pubmed.ncbi.nlm.nih.gov/23059747/
21.Peng, X., et al. The association risk of male subfertility and testicular cancer: a systematic review. PLoS One, 2009. 4: e5591.
https://pubmed.ncbi.nlm.nih.gov/19440348/
22.Seikkula, H., et al. Familial aggregation of testicular cancer among early-onset cancer survivors. A prospective observational cohort data from Finland. Cancer Epidemiol, 2020. 69: 101807.
https://pubmed.ncbi.nlm.nih.gov/33045472/
23.Pluta, J., et al. Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nat Commun, 2021. 12: 4487.
https://pubmed.ncbi.nlm.nih.gov/34301922/
24.Moch, H., et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 2022. 82: 458.
https://pubmed.ncbi.nlm.nih.gov/35853783/
25.Brierley, J.E., et al. The TNM Classification of Malignant Tumours 8th edition. 2016.
https://www.wiley.com/en-gb/TNM+Classification+of+Malignant+Tumours%2C+8th+Edition-
p-9781119263579
26.Amin, M.B., et al. AJCC Cancer Staging Manual. 8th ed. 2017. P. 727.
https://link.springer.com/book/9783319406176
27.Klepp, O., et al. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol, 1990. 1: 281.
https://pubmed.ncbi.nlm.nih.gov/1702312/
28.Verhoeven, R.H., et al. Markedly increased incidence and improved survival of testicular cancer in the Netherlands. Acta Oncol, 2014. 53: 342.
https://pubmed.ncbi.nlm.nih.gov/23992111/
29.Warde, P., et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol, 2002. 20: 4448.
https://pubmed.ncbi.nlm.nih.gov/12431967/
30.Aparicio, J., et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol, 2005. 23: 8717.
https://pubmed.ncbi.nlm.nih.gov/16260698/
31.Chung, P., et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med, 2015. 4: 155.
https://pubmed.ncbi.nlm.nih.gov/25236854/
32.Mortensen, M.S., et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol, 2014. 66: 1172.
https://pubmed.ncbi.nlm.nih.gov/25064686/
33.Aparicio, J., et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol, 2014. 25: 2173.
https://pubmed.ncbi.nlm.nih.gov/25210015/
34.Tandstad, T., et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol, 2016. 27: 1299.
https://pubmed.ncbi.nlm.nih.gov/27052649/
35.Boormans, J.L., et al. Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. Eur Urol, 2017.
https://pubmed.ncbi.nlm.nih.gov/29100813/
36.Zengerling, F., et al. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review. Urol Oncol, 2017.
https://pubmed.ncbi.nlm.nih.gov/28712790/
37.Verrill, C., et al. Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am
J Surg Pathol, 2018. 42: e33.
https://pubmed.ncbi.nlm.nih.gov/29579010/
38.Albers, P., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol, 2003. 21: 1505.
https://pubmed.ncbi.nlm.nih.gov/12697874/
39.Blok, J.M., et al. Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis. BJU Int, 2020. 125: 355.
https://pubmed.ncbi.nlm.nih.gov/31797520/
40.Lobo, J., et al. Interobserver Agreement in Vascular Invasion Scoring and the Added Value of Immunohistochemistry for Vascular Markers to Predict Disease Relapse in Stage I Testicular Nonseminomas. Am J Surg Pathol, 2019. 43: 1711.
https://pubmed.ncbi.nlm.nih.gov/31490238/
41.Mead, G.M., et al. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol), 1997. 9: 207.
https://pubmed.ncbi.nlm.nih.gov/9315391/
42.Gillessen, S., et al. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol, 2021. 39: 1563.
https://pubmed.ncbi.nlm.nih.gov/33822655/
43.Beyer, J., et al. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J Clin Oncol, 2021. 39: 1553.
https://pubmed.ncbi.nlm.nih.gov/33729863/
44.Germa-Lluch, J.R., et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol, 2002. 42: 553.
https://pubmed.ncbi.nlm.nih.gov/12477650/
45.Angulo, J.C., et al. Clinicopathological study of regressed testicular tumors (apparent extragonadal germ cell neoplasms). J Urol, 2009. 182: 2303.
https://pubmed.ncbi.nlm.nih.gov/19762049/
46.Shaw, J. Diagnosis and treatment of testicular cancer. Am Fam Physician, 2008. 77: 469. 18326165
https://pubmed.ncbi.nlm.nih.gov/18326165/
47.Feldman, D.R., et al. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. J Clin Oncol, 2016. 34: 345.
https://pubmed.ncbi.nlm.nih.gov/26460295/
48.Tsili, A.C., et al. When to ask for an MRI of the scrotum. Andrology, 2021. 9: 1395.
https://pubmed.ncbi.nlm.nih.gov/33964115/
49.Sohaib, S.A., et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol, 2009. 64: 362.
https://pubmed.ncbi.nlm.nih.gov/19264179/
50.de Wit, M., et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol, 2008. 19: 1619.
https://pubmed.ncbi.nlm.nih.gov/18453520/
51.Huddart, R.A., et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol, 2007. 25: 3090.
https://pubmed.ncbi.nlm.nih.gov/17634488/
52.Oechsle, K., et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol, 2008. 26: 5930.
https://pubmed.ncbi.nlm.nih.gov/19018083/
53.Dieckmann, K.P., et al. Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment. Biomed Res Int, 2019. 2019: 5030349.
https://pubmed.ncbi.nlm.nih.gov/31275973/
54.Barlow, L.J., et al. Serum tumor markers in the evaluation of male germ cell tumors. Nat Rev Urol, 2010. 7: 610.
https://pubmed.ncbi.nlm.nih.gov/21068762/
55.Gilligan, T.D., et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol, 2010. 28: 3388.
https://pubmed.ncbi.nlm.nih.gov/20530278/
56.Nicholson, B.D., et al. The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: A diagnostic test accuracy systematic review. Cancer Epidemiol, 2019. 59: 15.
https://pubmed.ncbi.nlm.nih.gov/30658216/
57.Leão, R., et al. Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review. Eur Urol, 2021. 80: 456.
https://pubmed.ncbi.nlm.nih.gov/34175151/
58.Lobo, J., et al. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. Eur Urol Oncol, 2021. 4: 483.
https://pubmed.ncbi.nlm.nih.gov/33288479/
59.Belge, G., et al. Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin. J Cancer Res Clin Oncol, 2021. 147: 435.
https://pubmed.ncbi.nlm.nih.gov/33200255/
60.Patel, H.D., et al. Testis-sparing surgery and scrotal violation for testicular masses suspicious for malignancy: A systematic review and meta-analysis. Urol Oncol, 2020. 38: 344.
https://pubmed.ncbi.nlm.nih.gov/32192891/
61.Loy, V., et al. Incidence and distribution of carcinoma in situ in testes removed for germ cell tumour: possible inadequacy of random testicular biopsy in detecting the condition. Histopathology, 1990. 16: 198.
https://pubmed.ncbi.nlm.nih.gov/2323743/
62.Dieckmann, K.P., et al. Carcinoma in situ of the testis: review of biological and clinical features. Int
J Cancer, 1999. 83: 815.
https://pubmed.ncbi.nlm.nih.gov/10597201/
63.Nason, G.J., et al. Partial orchiectomy: The Princess Margaret cancer centre experience. Urol Oncol, 2020. 38: 605 e19.
https://pubmed.ncbi.nlm.nih.gov/32284257/
64.Dieckmann, K.P., et al. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol, 2007. 51: 175.
https://pubmed.ncbi.nlm.nih.gov/16814456/
65.Fankhauser, C.D., et al. The Role of Frozen Section Examination During Inguinal Exploration in Men with Inconclusive Testicular Tumors: A Systematic Review and Meta-analysis. Eur Urol Focus, 2020.
https://pubmed.ncbi.nlm.nih.gov/32684510/
66.Bieniek, J.M., et al. Prevalence and Management of Incidental Small Testicular Masses Discovered on Ultrasonographic Evaluation of Male Infertility. J Urol, 2018. 199: 481.
https://pubmed.ncbi.nlm.nih.gov/28789946/
67.Scandura, G., et al. Incidentally detected testicular lesions <10 mm in diameter: can orchidectomy be avoided? BJU Int, 2018. 121: 575.
https://pubmed.ncbi.nlm.nih.gov/29032579/
68.Matei, D.V., et al. Reliability of Frozen Section Examination in a Large Cohort of Testicular Masses: What Did We Learn? Clin Genitourin Cancer, 2017. 15: e689.
https://pubmed.ncbi.nlm.nih.gov/28216275/
69.Elert, A., et al. Accuracy of frozen section examination of testicular tumors of uncertain origin. Eur Urol, 2002. 41: 290.
https://pubmed.ncbi.nlm.nih.gov/12180230/
70.Favilla, V., et al. Oncological and functional outcomes of testis sparing surgery in small testicular mass: a systematic review. Minerva Urol Nephrol, 2021. 73: 431.
https://pubmed.ncbi.nlm.nih.gov/33949185/
71.Skoogh, J., et al. Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. Int J Androl, 2011. 34: 183.
https://pubmed.ncbi.nlm.nih.gov/20550599/
72.Robinson, R., et al. Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy. BJU Int, 2016. 117: 249.
https://pubmed.ncbi.nlm.nih.gov/25168859/
73.Dieckmann, K.P., et al. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol, 1996. 14: 3126.
https://pubmed.ncbi.nlm.nih.gov/8955658/
74.Ruf, C.G., et al. Contralateral biopsies in patients with testicular germ cell tumours: patterns of care in Germany and recent data regarding prevalence and treatment of testicular intra-epithelial neoplasia. Andrology, 2015. 3: 92.
https://pubmed.ncbi.nlm.nih.gov/25146646/
75.Andreassen, K.E., et al. Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953-2007). Int J Cancer, 2011. 129: 2867.
https://pubmed.ncbi.nlm.nih.gov/21626506/
76.Harland, S.J., et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol, 1998. 160: 1353.
https://pubmed.ncbi.nlm.nih.gov/9751353/
77.Tabernero, J., et al. Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. J Urol, 2004. 171: 164.
https://pubmed.ncbi.nlm.nih.gov/14665868/
78.Albers, P., et al. Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. Urology, 1999. 54: 714.
https://pubmed.ncbi.nlm.nih.gov/10510934/
79.Heidenreich, A., et al. Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated? Semin Urol Oncol, 2002. 20: 234.
https://pubmed.ncbi.nlm.nih.gov/12489055/
80.Giwercman, A., et al. Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism. J Urol, 1989. 142: 998.
https://pubmed.ncbi.nlm.nih.gov/2571738/
81.Souchon, R., et al. Contralateral testicular cancer in spite of TIN-negative double biopsies and interval cisplatin chemotherapy. Strahlenther Onkol, 2006. 182: 289.
https://pubmed.ncbi.nlm.nih.gov/16673063/
82.Moch, H.H., et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. 2016, Lyon.
83.Verrill, C., et al. Reporting and Staging of Testicular Germ Cell Tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am
J Surg Pathol, 2017. 41: e22.
https://pubmed.ncbi.nlm.nih.gov/28368923/
84.Berney, D.M., et al. Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. Histopathology, 2019. 74: 171.
https://pubmed.ncbi.nlm.nih.gov/30565308/
85.Kuczyk, M.A., et al. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis. Cancer, 1996. 78: 1958.
https://pubmed.ncbi.nlm.nih.gov/8909317/
86.U.S. Preventive Services Task Force. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med, 2011. 154: 483.
https://pubmed.ncbi.nlm.nih.gov/21464350/
87.Ilic, D., et al. Screening for testicular cancer. Cochrane Database Syst Rev, 2011: CD007853.
https://pubmed.ncbi.nlm.nih.gov/21328302/
88.Thornton, C.P. Best Practice in Teaching Male Adolescents and Young Men to Perform Testicular Self-Examinations: A Review. J Pediatr Health Care, 2016. 30: 518.
https://pubmed.ncbi.nlm.nih.gov/26778347/
89.Bandak, M., et al. Preorchiectomy Leydig Cell Dysfunction in Patients With Testicular Cancer. Clin Genitourin Cancer, 2017. 15: e37.
https://pubmed.ncbi.nlm.nih.gov/27524512/
90.Rives, N., et al. The semen quality of 1158 men with testicular cancer at the time of cryopreservation: results of the French National CECOS Network. J Androl, 2012. 33: 1394.
https://pubmed.ncbi.nlm.nih.gov/22837112/
91.Petersen, P.M., et al. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. J Urol, 1999. 161: 822.
https://pubmed.ncbi.nlm.nih.gov/10022693/
92.Brydoy, M., et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol, 2010. 58: 134.
https://pubmed.ncbi.nlm.nih.gov/20395037/
93.Brydoy, M., et al. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. Br J Cancer, 2012. 107: 1833.
https://pubmed.ncbi.nlm.nih.gov/23169336/
94.Petersen, P.M., et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol, 2002. 20: 1537.
https://pubmed.ncbi.nlm.nih.gov/11896102/
95.Lampe, H., et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol, 1997.
15: 239.
https://pubmed.ncbi.nlm.nih.gov/8996148/
96.Weibring, K., et al. Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment. Ann Oncol, 2019. 30: 604.
https://pubmed.ncbi.nlm.nih.gov/30798330/
97.Gilbert, K., et al. Fertility preservation for men with testicular cancer: Is sperm cryopreservation cost effective in the era of assisted reproductive technology? Urol Oncol, 2018. 36: 92 e1.
https://pubmed.ncbi.nlm.nih.gov/29169844/
98.Jacobsen, K.D., et al. Gonadal function and fertility in patients with bilateral testicular germ cell malignancy. Eur Urol, 2002. 42: 229.
https://pubmed.ncbi.nlm.nih.gov/12234507/
99.Arnon, J., et al. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update, 2001. 7: 394.
https://pubmed.ncbi.nlm.nih.gov/11476352/
100.Salonia, A., et al., EAU Guidelines on Sexual and Reproductive Health, in European Association of Urology Guidelines. 2022. 2022, The European Association of Urology: Arnhem, The Netherlands.
https://uroweb.org/guidelines/sexual-and-reproductive-health
101.Hoei-Hansen, C.E., et al. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol, 2005. 16: 863.
https://pubmed.ncbi.nlm.nih.gov/15821122/
102.Dieckmann, K.P., et al. Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: a survey of the German Testicular Cancer Study Group. Ann Oncol, 2013. 24: 1332.
https://pubmed.ncbi.nlm.nih.gov/23293116/
103.Classen, J., et al. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer, 2003. 88: 828.
https://pubmed.ncbi.nlm.nih.gov/12644817/
104.Stephenson, A., et al. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline.
J Urol, 2019. 202: 272.
https://pubmed.ncbi.nlm.nih.gov/31059667/
105.Christensen, T.B., et al. Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol, 1998. 9: 657.
https://pubmed.ncbi.nlm.nih.gov/9681081/
106.Mortensen, M.S., et al. Treatment options for carcinoma in situ testis. Int J Androl, 2011. 34: e32.
https://pubmed.ncbi.nlm.nih.gov/21651575/
107.Bokemeyer, C., et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol, 2002. 20: 1864.
https://pubmed.ncbi.nlm.nih.gov/11919246/
108.Kollmannsberger, C., et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol, 2015. 33: 51.
https://pubmed.ncbi.nlm.nih.gov/25135991/
109.Groll, R.J., et al. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol, 2007. 64: 182.
https://pubmed.ncbi.nlm.nih.gov/17644403/
110.Nayan, M., et al. Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. Eur Urol, 2017. 71: 120.
https://pubmed.ncbi.nlm.nih.gov/27527805/
111.Tandstad, T., et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol, 2011. 29: 719.
https://pubmed.ncbi.nlm.nih.gov/21205748/
112.Chung, P., et al. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol), 2010. 22: 6.
https://pubmed.ncbi.nlm.nih.gov/19775876/
113.Huang, M.M., et al. Cost-effectiveness Analysis of Non-risk-adapted Active Surveillance for Postorchiectomy Management of Clinical Stage I Seminoma. Eur Urol Focus, 2020.
https://pubmed.ncbi.nlm.nih.gov/32646809/
114.Oliver, R.T., et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol, 2011. 29: 957.
https://pubmed.ncbi.nlm.nih.gov/21282539/
115.Fischer, S., et al. Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. J Clin Oncol, 2017. 35: 194.
https://pubmed.ncbi.nlm.nih.gov/27893332/
116.Bieri, S., et al. Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol, 1999. 50: 349.
https://pubmed.ncbi.nlm.nih.gov/10392822/
117.van den Belt-Dusebout, A.W., et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol, 2007. 25: 4370.
https://pubmed.ncbi.nlm.nih.gov/17906202/
118.Horwich, A., et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer, 2014. 110: 256.
https://pubmed.ncbi.nlm.nih.gov/24263066/
119.Patel, H.D., et al. Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. Urol Oncol, 2017. 35: 606 e1.
https://pubmed.ncbi.nlm.nih.gov/28712791/
120.Aparicio, J., et al. Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group. Clin Transl Oncol, 2021. 23: 58.
https://pubmed.ncbi.nlm.nih.gov/32462393/
121.Hamilton, R.J., et al. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. J Clin Oncol, 2019. 37: 1919.
https://pubmed.ncbi.nlm.nih.gov/30802156/
122.Kollmannsberger, C., et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol, 2010. 21: 1296.
https://pubmed.ncbi.nlm.nih.gov/19875756/
123.Nichols, C.R., et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol, 2013. 31: 3490.
https://pubmed.ncbi.nlm.nih.gov/24002502/
124.Donohue, J.P., et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol, 1993. 149: 237.
https://pubmed.ncbi.nlm.nih.gov/8381190/
125.Nicolai, N., et al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol, 2010. 58: 912.
https://pubmed.ncbi.nlm.nih.gov/20817343/
126.Nicolai, N., et al. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. J Urol, 2018. 199: 741.
https://pubmed.ncbi.nlm.nih.gov/28964782/
127.Al-Ahmadie, H.A., et al. Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy. Urology, 2013. 82: 1341.
https://pubmed.ncbi.nlm.nih.gov/24094656/
128.Douglawi, A., et al. Long-Term Oncologic Outcomes after Primary Retroperitoneal Lymph Node Dissection: Minimizing the Need for Adjuvant Chemotherapy. J Urol, 2020. 204: 96.
https://pubmed.ncbi.nlm.nih.gov/32003612/
129.Tachibana, I., et al. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol, 2022. 40: 3762.
https://pubmed.ncbi.nlm.nih.gov/35675585/
130.Heidenreich, A., et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol, 2003. 169: 1710.
https://pubmed.ncbi.nlm.nih.gov/12686815/
131.Albers, P., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol, 2008. 26: 2966.
https://pubmed.ncbi.nlm.nih.gov/18458040/
132.Pearce, S.M., et al. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol, 2017. 71: 476.
https://pubmed.ncbi.nlm.nih.gov/27234998/
133.Calaway, A.C., et al. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol, 2019. 76: 607.
https://pubmed.ncbi.nlm.nih.gov/31174891/
134.Rodrigues, G.J., et al. Robot-assisted retroperitoneal lymphadenectomy: The state of art. Asian
J Urol, 2021. 8: 27.
https://pubmed.ncbi.nlm.nih.gov/33569270/
135.Bhanvadia, R., et al. Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. World J Urol, 2021. 39: 1977.
https://pubmed.ncbi.nlm.nih.gov/32797261/
136.Schermerhorn, S.M.V., et al. Learning Curve for Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection. J Endourol, 2021. 35: 1483.
https://pubmed.ncbi.nlm.nih.gov/33559522/
137.Supron, A.D., et al. Primary robotic retroperitoneal lymph node dissection following orchiectomy for testicular germ cell tumors: a single-surgeon experience. J Robot Surg, 2021. 15: 309.
https://pubmed.ncbi.nlm.nih.gov/32572754/
138.Taylor, J., et al. Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort. Eur Urol Focus, 2020.
https://pubmed.ncbi.nlm.nih.gov/32682794/
139.Hiester, A., et al. Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer. J Urol, 2020. 204: 1242.
https://pubmed.ncbi.nlm.nih.gov/32717162/
140.Foster, R.S., et al. Clinical stage I nonseminoma: surgery versus surveillance. Semin Oncol, 1998. 25: 145.
https://pubmed.ncbi.nlm.nih.gov/9562447/
141.Cullen, M.H., et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol, 1996. 14: 1106.
https://pubmed.ncbi.nlm.nih.gov/8648364/
142.Pont, J., et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol, 1996. 14: 441.
https://pubmed.ncbi.nlm.nih.gov/8636755/
143.Chevreau, C., et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol, 2004. 46: 209.
https://pubmed.ncbi.nlm.nih.gov/15245815/
144.Bohlen, D., et al. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol, 2001. 165: 441.
https://pubmed.ncbi.nlm.nih.gov/11176393/
145.Tandstad, T., et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol, 2009. 27: 2122.
https://pubmed.ncbi.nlm.nih.gov/19307506/
146.Tandstad, T., et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol, 2014. 25: 2167.
https://pubmed.ncbi.nlm.nih.gov/25114021/
147.Flechtner, H.H., et al. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours. Eur Urol, 2016. 69: 518.
https://pubmed.ncbi.nlm.nih.gov/26620368/
148.Huddart, R.A., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol, 2003. 21: 1513.
https://pubmed.ncbi.nlm.nih.gov/12697875/
149.Westermann, D.H., et al. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. J Urol, 2008. 179: 163.
https://pubmed.ncbi.nlm.nih.gov/18001800/
150.Fischer, S., et al. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. J Clin Oncol, 2020. 38: 1322.
https://pubmed.ncbi.nlm.nih.gov/31877087/
151.Giannatempo, P., et al. Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. J Urol, 2016. 196: 95.
https://pubmed.ncbi.nlm.nih.gov/26748165/
152.Hajiran, A., et al. Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Ann Surg Oncol, 2021. 28: 3648.
https://pubmed.ncbi.nlm.nih.gov/33689081/
153.Harari, S.E., et al. Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens. Urol Oncol, 2017. 35: 605.e9.
https://pubmed.ncbi.nlm.nih.gov/28647396/
154.Lorch, A., et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol, 2010. 28: 4906.
https://pubmed.ncbi.nlm.nih.gov/20956623/
155.Aparicio, J., et al. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group. J Urol, 2019. 202: 742.
https://pubmed.ncbi.nlm.nih.gov/31163007/
156.Classen, J., et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol, 2003. 21: 1101.
https://pubmed.ncbi.nlm.nih.gov/12637477/
157.Chung, P.W., et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol, 2004. 45: 754.
https://pubmed.ncbi.nlm.nih.gov/15149748/
158.Culine, S., et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol, 2007. 18: 917.
https://pubmed.ncbi.nlm.nih.gov/17351252/
159.Giannatempo, P., et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol, 2015. 26: 657.
https://pubmed.ncbi.nlm.nih.gov/25214543/
160.Hellesnes, R., et al. Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era. Int J Cancer, 2020. 147: 21.
https://pubmed.ncbi.nlm.nih.gov/31597192/
161.Hu, B., et al. Retroperitoneal Lymph Node Dissection as First-Line Treatment of Node-Positive Seminoma. Clin Genitourin Cancer, 2015. 13: e265.
https://pubmed.ncbi.nlm.nih.gov/25682512/
162.Tabakin, A.L., et al. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. Clin Genitourin Cancer, 2020. 18: e194.
https://pubmed.ncbi.nlm.nih.gov/31818649/
163.Baniel, J., et al. Late relapse of testicular cancer. J Clin Oncol, 1995. 13: 1170.
https://pubmed.ncbi.nlm.nih.gov/7537800/
164.Stephenson, A.J., et al. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
J Clin Oncol, 2007. 25: 5597.
https://pubmed.ncbi.nlm.nih.gov/18065732/
165.Neuenschwander, A., et al. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. Eur Urol Focus, 2022.
https://pubmed.ncbi.nlm.nih.gov/36379869/
166.Nicolai, N., et al. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: evaluation of safety and efficacy. Tumori J, 2022.
https://journals.sagepub.com/doi/epub/10.1177/03008916221112697
167.McHugh, D.J., et al. Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. J Clin Oncol, 2020. 38: 1332.
https://pubmed.ncbi.nlm.nih.gov/32109195/
168.Bokemeyer, C., et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer, 2004. 91: 683.
https://pubmed.ncbi.nlm.nih.gov/15266338/
169.de Wit, R., et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol, 1997. 15: 1837.
https://pubmed.ncbi.nlm.nih.gov/9164193/
170.Fizazi, K., et al. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study. Eur Urol, 2014. 65: 381.
https://pubmed.ncbi.nlm.nih.gov/24094847/
171.de Wit, R., et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol, 2001. 19: 1629.
https://pubmed.ncbi.nlm.nih.gov/11250991/
172.Fossa, S.D., et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol, 2003. 21: 1107.
https://pubmed.ncbi.nlm.nih.gov/12637478/
173.Grimison, P.S., et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst, 2010. 102: 1253.
https://pubmed.ncbi.nlm.nih.gov/20631341/
174.Fossa, S.D., et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol, 1998. 16: 716.
https://pubmed.ncbi.nlm.nih.gov/9469362/
175.de Wit, R., et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer, 1998. 78: 828.
https://pubmed.ncbi.nlm.nih.gov/9743309/
176.Nichols, C.R., et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol, 1998. 16: 1287.
https://pubmed.ncbi.nlm.nih.gov/9552027/
177.Daugaard, G., et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol, 2011. 22: 1054.
https://pubmed.ncbi.nlm.nih.gov/21059637/
178.Motzer, R.J., et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol, 2007. 25: 247.
https://pubmed.ncbi.nlm.nih.gov/17235042/
179.Fizazi, K., et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol, 2004. 22: 3868.
https://pubmed.ncbi.nlm.nih.gov/15302906/
180.Fizazi, K., et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol, 2014. 15: 1442.
https://pubmed.ncbi.nlm.nih.gov/25456363/
181.Kollmannsberger, C., et al. Identification of prognostic subgroups among patients with metastatic ‘IGCCCG poor-prognosis’ germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol, 2000. 11: 1115.
https://pubmed.ncbi.nlm.nih.gov/11061604/
182.Winter, C., et al. How to classify, diagnose, treat and follow-up extragonadal germ cell tumors?
A systematic review of available evidence. World J Urol, 2022.
https://pubmed.ncbi.nlm.nih.gov/35554637/
183.Collette, L., et al. Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst, 1999. 91: 839.
https://pubmed.ncbi.nlm.nih.gov/10340903/
184.Massard, C., et al. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? Ann Oncol, 2010. 21: 1585.
https://pubmed.ncbi.nlm.nih.gov/20181575/
185.Woldu, S.L., et al. Impact of hospital case volume on testicular cancer outcomes and practice patterns. Urol Oncol, 2018. 36: 14.e7.
https://pubmed.ncbi.nlm.nih.gov/28935185/
186.Gillessen, S., et al. Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience. Ann Oncol, 2010.
21: 1589.
https://pubmed.ncbi.nlm.nih.gov/20164149/
187.Khorana, A.A., et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. New Engl J Med, 2019. 380: 720.
https://pubmed.ncbi.nlm.nih.gov/30786186/
188.Carrier, M., et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl
J Med, 2019. 380: 711.
https://pubmed.ncbi.nlm.nih.gov/30511879/
189.Agnelli, G., et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med, 2012. 366: 601.
https://pubmed.ncbi.nlm.nih.gov/22335737/
190.Agnelli, G., et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol, 2009. 10: 943.
https://pubmed.ncbi.nlm.nih.gov/19726226/
191.Key, N.S., et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol, 2019. 38: 496.
https://pubmed.ncbi.nlm.nih.gov/31381464/
192.Gizzi, M., et al. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer, 2016. 69: 151.
https://pubmed.ncbi.nlm.nih.gov/27821318/
193.Fankhauser, C.D., et al. A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. Eur Urol Focus, 2021. 7: 1130.
https://pubmed.ncbi.nlm.nih.gov/33032968/
194.Haugnes, H.S., et al. Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000–2014: A Population-based Cohort Study. Eur Urol Open Sci, 2021. 32: 19.
https://pubmed.ncbi.nlm.nih.gov/34667955/
195.Gizzi, M., et al. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer, 2016. 69: 151.
https://pubmed.ncbi.nlm.nih.gov/27821318/
196.Andre, F., et al. The growing teratoma syndrome: results of therapy and long-term follow-up of
33 patients. Eur J Cancer, 2000. 36: 1389.
https://pubmed.ncbi.nlm.nih.gov/10899652/
197.Fossa, S.D., et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer, 1999. 80: 1392.
https://pubmed.ncbi.nlm.nih.gov/10424741/
198.Hofmockel, G., et al. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol Int, 1996. 57: 38.
https://pubmed.ncbi.nlm.nih.gov/8840489/
199.Kamat, M.R., et al. Value of retroperitoneal lymph node dissection in advanced testicular seminoma. J Surg Oncol, 1992. 51: 65.
https://pubmed.ncbi.nlm.nih.gov/1381455/
200.Motzer, R., et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol, 1987. 5: 1064.
https://pubmed.ncbi.nlm.nih.gov/3598610/
201.De Santis, M., et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol, 2004. 22: 1034.
https://pubmed.ncbi.nlm.nih.gov/15020605/
202.Bachner, M., et al. 2-(1)(8)fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol, 2012. 23: 59.
https://pubmed.ncbi.nlm.nih.gov/21460378/
203.Beyer, J., et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol, 2013. 24: 878.
https://pubmed.ncbi.nlm.nih.gov/23152360/
204.Cathomas, R., et al. Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol, 2018. 36: JCO1800210.
https://pubmed.ncbi.nlm.nih.gov/30285559/
205.Herr, H.W., et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol, 1997. 157: 860.
https://pubmed.ncbi.nlm.nih.gov/9072586/
206.Mosharafa, A.A., et al. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol, 2003. 169: 2126.
https://pubmed.ncbi.nlm.nih.gov/12771733/
207.Puc, H.S., et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol, 1996. 14: 454.
https://pubmed.ncbi.nlm.nih.gov/8636757/
208.Carver, B.S., et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol, 2007. 25: 5603.
https://pubmed.ncbi.nlm.nih.gov/17998544/
209.Nason, G.J., et al. Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. Eur Urol Oncol, 2021. 4: 289.
https://pubmed.ncbi.nlm.nih.gov/32907779/
210.Ehrlich, Y., et al. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol, 2010. 28: 531.
https://pubmed.ncbi.nlm.nih.gov/20026808/
211.Hartmann, J.T., et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur
J Cancer, 1997. 33: 843.
https://pubmed.ncbi.nlm.nih.gov/9291803/
212.Hendry, W.F., et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer, 2002. 94: 1668.
https://pubmed.ncbi.nlm.nih.gov/11920527/
213.Sheinfeld, J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol, 2002. 20: 262.
https://pubmed.ncbi.nlm.nih.gov/12489059/
214.Steyerberg, E.W., et al. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. Int J Cancer, 1999. 83: 856.
https://pubmed.ncbi.nlm.nih.gov/10597211/
215.Carver, B.S., et al. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol, 2007. 25: 1033.
https://pubmed.ncbi.nlm.nih.gov/17261854/
216.Oldenburg, J., et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol, 2003.
21: 3310.
https://pubmed.ncbi.nlm.nih.gov/12947067/
217.Rick, O., et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol, 2004. 22: 3713.
https://pubmed.ncbi.nlm.nih.gov/15365067/
218.Heidenreich, A., et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol, 2009. 55: 217.
https://pubmed.ncbi.nlm.nih.gov/18926622/
219.Gerdtsson, A., et al. Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group. Eur Urol Oncol, 2021.
https://pubmed.ncbi.nlm.nih.gov/33750683/
220.Beck, S.D., et al. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer, 2007. 110: 1235.
https://pubmed.ncbi.nlm.nih.gov/17665498/
221.Large, M.C., et al. Retroperitoneal lymph node dissection: reassessment of modified templates. BJU Int, 2009. 104: 1369.
https://pubmed.ncbi.nlm.nih.gov/19840015/
222.Fizazi, K., et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol, 2008. 19: 259.
https://pubmed.ncbi.nlm.nih.gov/18042838/
223.Busch, J., et al. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis. BMC Urol, 2012. 12: 15.
https://pubmed.ncbi.nlm.nih.gov/22651395/
224.Arai, Y., et al. Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes. Int Urol Nephrol, 2012. 44: 1389.
https://pubmed.ncbi.nlm.nih.gov/22648291/
225.Nicolai, N., et al. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. J Endourol, 2016. 30: 1112.
https://pubmed.ncbi.nlm.nih.gov/27533924/
226.Stepanian, S., et al. Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique. Eur Urol, 2016. 70: 661.
https://pubmed.ncbi.nlm.nih.gov/27068395/
227.Steyerberg, E.W., et al. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. J Urol, 1997. 158: 474.
https://pubmed.ncbi.nlm.nih.gov/9224327/
228.Besse, B., et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg, 2009. 137: 448.
https://pubmed.ncbi.nlm.nih.gov/19185168/
229.Schirren, J., et al. The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. Thorac Cardiovasc Surg, 2012. 60: 405.
https://pubmed.ncbi.nlm.nih.gov/22383152/
230.Ehrlich, Y., et al. Vena caval reconstruction during postchemotherapy retroperitoneal lymph node dissection for metastatic germ cell tumor. Urology, 2009. 73: 442 e17.
https://pubmed.ncbi.nlm.nih.gov/18436290/
231.Heidenreich, A., et al. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. Ann Oncol, 2017. 28: 362.
https://pubmed.ncbi.nlm.nih.gov/27831507/
232.Winter, C., et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol, 2012. 61: 403.
https://pubmed.ncbi.nlm.nih.gov/22078334/
233.Wells, H., et al. Contemporary retroperitoneal lymph node dissection (RPLND) for testis cancer in the UK - a national study. BJU Int, 2017. 119: 91.
https://pubmed.ncbi.nlm.nih.gov/27353395/
234.Capitanio, U., et al. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. Urology, 2009. 74: 373.
https://pubmed.ncbi.nlm.nih.gov/19501893/
235.Flechon, A., et al. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int, 2010. 106: 779.
https://pubmed.ncbi.nlm.nih.gov/20089110/
236.Eggener, S.E., et al. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer, 2007. 109: 528.
https://pubmed.ncbi.nlm.nih.gov/17177200/
237.Oechsle, K., et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol, 2011. 60: 850.
https://pubmed.ncbi.nlm.nih.gov/21704446/
238.Nicolai, N., et al. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. BJU Int, 2009. 104: 340.
https://pubmed.ncbi.nlm.nih.gov/19239440/
239.Beck, S.D., et al. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol, 2005. 23: 6149.
https://pubmed.ncbi.nlm.nih.gov/16135481/
240.Fizazi, K., et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol, 2001. 19: 2647.
https://pubmed.ncbi.nlm.nih.gov/11352956/
241.Stenning, S.P., et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer, 1998. 83: 1409.
https://pubmed.ncbi.nlm.nih.gov/9762943/
242.Miller, K.D., et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol, 1997. 15: 1427.
https://pubmed.ncbi.nlm.nih.gov/9193335/
243.Fizazi, K., et al. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. Ann Oncol, 2014. 25: 987.
https://pubmed.ncbi.nlm.nih.gov/24595454/
244.Mead, G.M., et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer, 2005. 93: 178.
https://pubmed.ncbi.nlm.nih.gov/15999102/
245.Lorch, A., et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol, 2012. 30: 800.
https://pubmed.ncbi.nlm.nih.gov/22291076/
246.Oechsle, K., et al. Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor. Oncology, 2010. 78: 47.
https://pubmed.ncbi.nlm.nih.gov/20215785/
247.Agarwala, A.K., et al. Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma. Am J Clin Oncol, 2011. 34: 286.
https://pubmed.ncbi.nlm.nih.gov/20523207/
248.Berger, L.A., et al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Clin Oncol, 2014. 140: 1211.
https://pubmed.ncbi.nlm.nih.gov/24696231/
249.Massard, C., et al. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Ann Oncol, 2013. 24: 322.
https://pubmed.ncbi.nlm.nih.gov/23104726/
250.Necchi, A., et al. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant, 2016. 51: 384.
https://pubmed.ncbi.nlm.nih.gov/26642334/
251.Bin Riaz, I., et al. Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review. Bone Marrow Transplant, 2018. 53: 1242.
https://pubmed.ncbi.nlm.nih.gov/29703969/
252.Necchi, A., et al. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes. Clin Genitourin Cancer, 2014. 12: 63.
https://pubmed.ncbi.nlm.nih.gov/24161525/
253.Mulherin, B.P., et al. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. Am J Clin Oncol, 2015.
38: 373.
https://pubmed.ncbi.nlm.nih.gov/26214082/
254.Lorch, A., et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol, 2007. 25: 2778.
https://pubmed.ncbi.nlm.nih.gov/17602082/
255.Oldenburg, J., et al. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol, 2006. 24: 5503.
https://pubmed.ncbi.nlm.nih.gov/17158535/
256.Oldenburg, J., et al. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer, 2006. 94: 820.
https://pubmed.ncbi.nlm.nih.gov/16508636/
257.George, D.W., et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis.
J Clin Oncol, 2003. 21: 113.
https://pubmed.ncbi.nlm.nih.gov/12506179/
258.Lee, A.H., et al. The value of central histopathological review of testicular tumours before treatment. BJU Int, 1999. 84: 75.
https://pubmed.ncbi.nlm.nih.gov/10444128/
259.Lipphardt, M.E., et al. Late relapse of testicular cancer. World J Urol, 2004. 22: 47.
https://pubmed.ncbi.nlm.nih.gov/15064970/
260.Fossa, S.D., et al. Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer, 1999. 85: 988.
https://pubmed.ncbi.nlm.nih.gov/10091779/
261.Bokemeyer, C., et al. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol, 1997. 15: 1449.
https://pubmed.ncbi.nlm.nih.gov/9193339/
262.Hartmann J.T., et al. Multidiciplinary treatment and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumour (GCT) origin. Proc Ann Soc Clin Oncol, 2003. 22.
https://www.researchgate.net/publication/246472451_849
263.Honecker, F., et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol, 2018. 29: 1658.
https://pubmed.ncbi.nlm.nih.gov/30113631/
264.Hale, G.R., et al. Lymph node imaging in testicular cancer. Transl Androl Urol, 2018. 7: 864.
https://pubmed.ncbi.nlm.nih.gov/30456189/
265.Thomas, K.L., et al. The role of diagnostic imaging in the primary testicular cancer: initial staging, response assessment and surveillance. Transl Androl Urol, 2020. 9: S3.
https://pubmed.ncbi.nlm.nih.gov/32055480/
266.Laukka, M., et al. Comparison between CT and MRI in detection of metastasis of the retroperitoneum in testicular germ cell tumors: a prospective trial. Acta Oncol, 2020. 59: 660.
https://pubmed.ncbi.nlm.nih.gov/32048533/
267.Loughrey, G.J., et al. The value of specialist oncological radiology review of cross-sectional imaging. Clin Radiol, 1999. 54: 149.
https://pubmed.ncbi.nlm.nih.gov/10201861/
268.Larsen, S.K.A., et al. Ten years of experience with MRI follow-up of testicular cancer stage I: a retrospective study and an MRI protocol with DWI. Acta Oncol, 2020. 59: 1374.
https://pubmed.ncbi.nlm.nih.gov/32684054/
269.Mortensen, M.S., et al. Late Relapses in Stage I Testicular Cancer Patients on Surveillance. Eur Urol, 2016. 70: 365.
https://pubmed.ncbi.nlm.nih.gov/26996661/
270.Travis, L.B., et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst, 2010. 102: 1114.
https://pubmed.ncbi.nlm.nih.gov/20585105/
271.Agrawal, V., et al. Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management. JNCI Cancer Spectr, 2020. 4: pkz079.
https://pubmed.ncbi.nlm.nih.gov/32190815/
272.Kerns, S.L., et al. Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. JNCI Cancer Spectr, 2020. 4: pkaa022.
https://pubmed.ncbi.nlm.nih.gov/32704617/
273.Haugnes, H.S., et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol, 2012. 30: 3752.
https://pubmed.ncbi.nlm.nih.gov/23008318/
274.Alberti, K.G., et al. The metabolic syndrome--a new worldwide definition. Lancet, 2005. 366: 1059.
https://pubmed.ncbi.nlm.nih.gov/16182882/
275.Giannoulatou, E., et al. Whole-genome sequencing of spermatocytic tumors provides insights into the mutational processes operating in the male germline. PLoS One, 2017. 12: e0178169.
https://pubmed.ncbi.nlm.nih.gov/28542371/
276.Moch, H., et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 2016. 70: 93.
https://pubmed.ncbi.nlm.nih.gov/26935559/
277.Grogg, J.B., et al. A systematic review of treatment outcomes in localised and metastatic spermatocytic tumors of the testis. J Cancer Res Clin Oncol, 2019. 145: 3037.
https://pubmed.ncbi.nlm.nih.gov/31646373/
278.Idrees, M.T., et al. The World Health Organization 2016 classification of testicular non-germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017. 70: 513.
https://pubmed.ncbi.nlm.nih.gov/27801954/
279.Ruf, C.G., et al. Leydig-cell tumour of the testis: retrospective analysis of clinical and therapeutic features in 204 cases. World J Urol, 2020. 38: 2857.
https://pubmed.ncbi.nlm.nih.gov/31960106/
280.Fankhauser, C.D., et al. Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. J Urol, 2020. 203: 949.
https://pubmed.ncbi.nlm.nih.gov/31845841/
281.Grogg, J., et al. Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients. Oncologist, 2020. 25: 585.
https://pubmed.ncbi.nlm.nih.gov/32043680/
282.Grogg, J.B., et al. Risk factors and treatment outcomes of 239 patients with testicular granulosa cell tumors: a systematic review of published case series data. J Cancer Res Clin Oncol, 2020.
146: 2829.
https://pubmed.ncbi.nlm.nih.gov/32719989/
283.Zhang, M., et al. Testicular fibrothecoma: a morphologic and immunohistochemical study of 16 cases. Am J Surg Pathol, 2013. 37: 1208.
https://pubmed.ncbi.nlm.nih.gov/23715159/
284.Bhambhvani, H.P., et al. Primary malignancies of the epididymis: clinical characteristics and prognostic factors. Can J Urol, 2021. 28: 10522.
https://pubmed.ncbi.nlm.nih.gov/33625342/
285.Chowdhry, V.K., et al. Testicular, Spermatic Cord, and Scrotal Soft Tissue Sarcomas: Treatment Outcomes and Patterns of Failure. Sarcoma, 2021. 2021: 8824301.
https://pubmed.ncbi.nlm.nih.gov/33746565/
286.Radaelli, S., et al. Prognostic factors and outcome of spermatic cord sarcoma. Ann Surg Oncol, 2014. 21: 3557.
https://pubmed.ncbi.nlm.nih.gov/24802908/
287.Bharti, J.N., et al. Cytomorphological spectrum of epididymal nodules: An institution’s experience. Cytojournal, 2017. 14: 26.
https://pubmed.ncbi.nlm.nih.gov/29259652/
288.Tsili, A.C., et al. MRI of the scrotum: Recommendations of the ESUR Scrotal and Penile Imaging Working Group. Eur Radiol, 2018. 28: 31.
https://pubmed.ncbi.nlm.nih.gov/28698942/
289.Grogg, J.B., et al. Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. J Cancer Res Clin Oncol, 2021. 147: 2671.